Daclatasvir inhibits hepatitis C virus NS5A motility and hyper-accumulation of phosphoinositides

Virology

Volumn 476, Issue , 2015, Pages 168-179

  Chukkapalli, Vineela ^a   Berger, Kristi L ^a,c   Kelly, Sean M ^a   Thomas, Meryl ^b   Deiters, Alexander ^b   Randall, Glenn ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Direct acting anti virals; HCV replication complex; Phosphatidylinositol 4 kinase alpha; Phosphatidylinositol 4 phosphate

Indexed keywords

BACTERIAL ENZYME; DACLATASVIR; NONSTRUCTURAL PROTEIN 5A; PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITOL 4 KINASE III ALPHA; PHOSPHATIDYLINOSITOL 4 PHOSPHATE; PHOSPHATIDYLINOSITOL KINASE; POLYPROTEIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL PHOSPHATE 4-KINASE; PHOSPHOTRANSFERASE; PROTEIN BINDING; RNA DIRECTED RNA POLYMERASE; VIRAL PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME LOCALIZATION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NONHUMAN; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; STRUCTURE ANALYSIS; VIRUS REPLICATION; ANTAGONISTS AND INHIBITORS; CELL LINE; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HEPACIVIRUS; HEPATITIS C; METABOLISM; PHYSIOLOGY; VIROLOGY;

DROSOPHILA C VIRUS; HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; CELL LINE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMIDAZOLES; PHOSPHATIDYLINOSITOLS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN BINDING; PROTEIN TRANSPORT; RNA REPLICASE; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84921317221     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.12.018     Document Type: Article

References (57)

1. Appel N., et al. Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly. PLoS. Pathog. 2008, 4(3):e1000035.
2. Ascher D.B., et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci. Rep. 2014, 4:4765.
3. Au J.S., Pockros P.J. Novel therapeutic approaches for hepatitis C. Clin. Pharmacol. Ther. 2014, 95(1):78-88.
4. Balla A., et al. A plasma membrane pool of phosphatidylinositol 4-phosphate is generated by phosphatidylinositol 4-kinase type-III alpha: studies with the PH domains of the oxysterol binding protein and FAPP1. Mol. Biol. Cell 2005, 16(3):1282-1295.
5. Barakat K.H., et al. A refined model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes. J. Chem. Inf. Model. 2014, (Epub ahead of print, April 14, 2014).
6. Berger K.L., Randall G. Potential roles for cellular cofactors in hepatitis C virus replication complex formation. Commun. Integr. Biol. 2009, 2(6):471-473.
7. Berger K.L., et al. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc. Natl. Acad. Sci. USA 2009, 106(18):7577-7582.
8. Berger K.L., et al. Hepatitis C virus stimulates the phosphatidylinositol 4-kinase III alpha-dependent phosphatidylinositol 4-phosphate production that is essential for its replication. J. Virol. 2011, 85(17):8870-8883.
9. Bhattacharya D., et al. Pharmacological disruption of hepatitis C NS5A protein intra- and intermolecular conformations. J. Gen. Virol. 2014, 95(Pt 2):363-372.
10. Bianco A., et al. Metabolism of phosphatidylinositol 4-kinase IIIalpha-dependent PI4P Is subverted by HCV and is targeted by a 4-anilino quinazoline with antiviral activity. PLoS Pathog. 2012, 8(3):e1002576.
11. Blight K.J., Kolykhalov A.A., Rice C.M. Efficient initiation of HCV RNA replication in cell culture. Science 2000, 290(5498):1972-1974.
12. Borawski J., et al. Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication. J. Virol. 2009, 83(19):10058-10074.
13. Chatel-Chaix L., et al. Direct-acting and host-targeting HCV inhibitors: current and future directions. Curr. Opin. Virol. 2012.
14. Chukkapalli V., Randall G. Hepatitis C virus replication compartment formation: mechanism and drug target. Gastroenterology 2014, 146(5):1164-1167.
15. Evans M.J., Rice C.M., Goff S.P. Phosphorylation of hepatitis C virus nonstructural protein 5A modulates its protein interactions and viral RNA replication. Proc. Natl. Acad. Sci. USA 2004, 101(35):13038-13043.
16. Eyre N.S., et al. Dynamic imaging of the hepatitis C virus NS5A protein during a productive infection. J. Virol. 2014, 88(7):3636-3652.
17. Fridell R.A., et al. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J. Virol. 2011, 85(14):7312-7320.
18. Gao M., et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010, 465(7294):96-100.
19. Gosert R., et al. Identification of the hepatitis C virus RNA replication complex in Huh-7 cells harboring subgenomic replicons. J. Virol. 2003, 77(9):5487-5492.
20. Gottwein J.M., et al. Development and application of hepatitis C reporter viruses with genotype 1-7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A. J. Virol. 2011, 85(17):8913-8928.
21. Guedj J., et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc. Natl. Acad. Sci. USA 2013, 110(10):3991-3996.
22. Hammond G.R., Schiavo G., Irvine R.F. Immunocytochemical techniques reveal multiple, distinct cellular pools of PtdIns4P and PtdIns(4,5)P(2). Biochem. J. 2009, 422(1):23-35.
23. Harak C., et al. Mapping of functional domains of the lipid kinase phosphatidylinositol 4-kinase type III alpha involved in enzymatic activity and hepatitis c virus replication. J. Virol. 2014.
24. He, Y., K.A. Staschke, S.L. Tan, 2006. HCV NS5A: a multifunctional regulator of cellular pathways and virus replication. In: , Tan,S.L. (Ed). Hepatitis C Viruses: Genomes and Molecular Biology, Norfolk, UK.
25. Huang Y., et al. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication. Virology 2007, 364(1):1-9.
26. Kaneko T., et al. Production of two phosphoproteins from the NS5A region of the hepatitis C viral genome. Biochem. Biophys. Res. Commun. 1994, 205(1):320-326.
27. Lambert S.M., et al. The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors. Protein Sci. 2014, 23(6):723-734.
28. Lee C., et al. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein. Virology 2011, 414(1):10-18.
29. Lemm J.A., et al. Identification of hepatitis C virus NS5A inhibitors. J. Virol. 2010, 84(1):482-491.
30. Li H., et al. Hepatitis C virus NS5A Hijacks ARFGAP1 to maintain a phosphatidylinositol 4-phosphate-enriched microenvironment. J. Virol. 2014, 88(11):5956-5966.
31. Li Q., et al. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc. Natl. Acad. Sci. USA 2009, 106(38):16410-16415.
32. Lim P.J., et al. Correlation between NS5A dimerization and Hepatitis C virus replication. J. Biol. Chem. 2012, 287(36):30861-30873.
33. Lohmann V., et al. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 2003, 77(5):3007-3019.
34. Love R.A., et al. Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus. J. Virol. 2009, 83(9):4395-4403.
35. Madan V., et al. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation. Gastroenterology 2014, 146(5):1361-1372. (e1-9).
36. Mateu G., et al. Intragenotypic JFH1 based recombinant hepatitis C virus produces high levels of infectious particles but causes increased cell death. Virology 2008, 376(2):397-407.
37. McGivern D.R., et al. Kinetic analyses reveal potent and early blockade of Hepatitis C virus assembly by NS5A inhibitors. Gastroenterology 2014.
38. Moradpour D., Penin F. Hepatitis C virus proteins: from structure to function. Curr. Top. Microbiol. Immunol. 2013, 369:113-142.
39. Moradpour D., et al. Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins. Hepatology 1998, 28(1):192-201.
40. Moradpour D., et al. Insertion of green fluorescent protein into nonstructural protein 5A allows direct visualization of functional hepatitis C virus replication complexes. J. Virol. 2004, 78(14):7400-7409.
41. O'Boyle Ii D.R., et al. Characterizations of HCV NS5A replication complex inhibitors. Virology 2013, 444(1-2):343-354.
42. Penin F., et al. Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A. J. Biol. Chem. 2004, 279(39):40835-40843.
43. Pietschmann T., et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. USA 2006, 103(19):7408-7413.
44. Qiu D., et al. The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization. J. Gen. Virol. 2011, 92(Pt 11):2502-2511.
45. Randall G., et al. Silencing of USP18 potentiates the antiviral activity of interferon against hepatitis C virus infection. Gastroenterology 2006, 131(5):1584-1591.
46. Reiss S., et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011, 9(1):32-45.
47. Reiss S., et al. The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A. PLoS Pathog. 2013, 9(5):e1003359.
48. Stedman C. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Ther. Adv. Gastroenterol. 2014, 7(3):131-140.
49. Tai A.W., Salloum S. The role of the phosphatidylinositol 4-kinase PI4KA in hepatitis C virus-induced host membrane rearrangement. PLoS One 2011, 6(10):e26300.
50. Tai A.W., et al. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 2009, 5(3):298-307.
51. Targett-Adams P., et al. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J. Virol. 2011, 85(13):6353-6368.
52. Tellinghuisen T.L., Marcotrigiano J., Rice C.M. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature 2005, 435(7040):374-379.
53. Trotard M., et al. Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening. FASEB J. 2009, 23(11):3780-3789.
54. Vaillancourt F.H., et al. Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication. Virology 2009, 387(1):5-10.
55. WHO. Available from: . http://www.who.int/mediacentre/factsheets/fs164/en/.
56. Wang H., et al. Oxysterol-binding protein is a phosphatidylinositol 4-kinase effector required for HCV replication membrane integrity and cholesterol trafficking. Gastroenterology 2014, 146(5):1373-1385. (e1-11).
57. Wolk B., et al. A dynamic view of hepatitis C virus replication complexes. J. Virol. 2008, 82(21):10519-10531.